Carvedilol: molecular and cellular basis for its multifaceted therapeutic potential.

Jianhua Cheng, K. Kamiya, Itsuo Kodama
{"title":"Carvedilol: molecular and cellular basis for its multifaceted therapeutic potential.","authors":"Jianhua Cheng, K. Kamiya, Itsuo Kodama","doi":"10.1111/J.1527-3466.2001.TB00061.X","DOIUrl":null,"url":null,"abstract":"Carvedilol is a unique cardiovascular drug of multifaceted therapeutic potential. Its major molecular targets recognized to date are membrane adrenoceptors (beta 1, beta 2, and alpha 1), reactive oxygen species, and ion channels (K+ and Ca2+). Carvedilol provides prominent hemodynamic benefits mainly through a balanced adrenoceptor blockade, which causes a reduction in cardiac work in association with peripheral vasodilation. This drug assures remarkable cardiovascular protection through its antiproliferative/atherogenic, antiischemic, antihypertrophic, and antiarrhythmic actions. These actions are a consequence of its potent antioxidant effects, amelioration of glucose/lipid metabolism, modulation of neurohumoral factors, and modulation of cardiac electrophysiologic properties. The usefulness of carvedilol in the treatment of hypertension, ischemic heart disease, and congestive heart failure is based on a combination of hemodynamic benefits and cardiovascular protection.","PeriodicalId":9490,"journal":{"name":"Cardiovascular drug reviews","volume":"64 1","pages":"152-71"},"PeriodicalIF":0.0000,"publicationDate":"2006-06-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"110","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cardiovascular drug reviews","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1111/J.1527-3466.2001.TB00061.X","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 110

Abstract

Carvedilol is a unique cardiovascular drug of multifaceted therapeutic potential. Its major molecular targets recognized to date are membrane adrenoceptors (beta 1, beta 2, and alpha 1), reactive oxygen species, and ion channels (K+ and Ca2+). Carvedilol provides prominent hemodynamic benefits mainly through a balanced adrenoceptor blockade, which causes a reduction in cardiac work in association with peripheral vasodilation. This drug assures remarkable cardiovascular protection through its antiproliferative/atherogenic, antiischemic, antihypertrophic, and antiarrhythmic actions. These actions are a consequence of its potent antioxidant effects, amelioration of glucose/lipid metabolism, modulation of neurohumoral factors, and modulation of cardiac electrophysiologic properties. The usefulness of carvedilol in the treatment of hypertension, ischemic heart disease, and congestive heart failure is based on a combination of hemodynamic benefits and cardiovascular protection.
卡维地洛:其多方面治疗潜力的分子和细胞基础。
卡维地洛是一种独特的心血管药物,具有多方面的治疗潜力。目前已知的主要分子靶点是膜肾上腺素受体(β 1、β 2和α 1)、活性氧和离子通道(K+和Ca2+)。卡维地洛主要通过平衡的肾上腺素能阻滞剂提供突出的血流动力学益处,这导致与周围血管舒张相关的心脏工作减少。该药物通过其抗增殖/动脉粥样硬化、抗缺血、抗肥厚和抗心律失常的作用,确保了显著的心血管保护作用。这些作用是其强大的抗氧化作用,改善糖/脂代谢,调节神经体液因子和心脏电生理特性的结果。卡维地洛在治疗高血压、缺血性心脏病和充血性心力衰竭中的作用是基于血流动力学益处和心血管保护的结合。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信